Michael Fice

Dr. Michael Fice

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in Rare Tumors
Verified
Journal Article
Open access
MFMichael Fice
Michael Fice
LLLinus Lee
Linus Lee
PKPavan Kottamasu
Pavan Kottamasu
AAAbdullah Almajnooni
Abdullah Almajnooni
MCMatthew R Cohn
Matthew R Cohn
ABAlan T Blank
Alan T Blank
Background: Extraskeletal myxoid chondrosarcoma (EMC) is a rare malignant soft tissue sarcoma (STS) that accounts for less than 3% of all soft tissue tumors. The conventional treatment for primary EMC is wide local excision with or without radiation therapy. Materials and Methods: This study was a retrospective review of all EMC cases treated within a single institution between 1992 and 2019. EMC was diagnosed using a combination of histologic morphology and immunostaining, with confirmatory fluorescent in situ hybridization. Overall survival (OS) and disease-specific survival (DSS) were defined using Kaplan–Meier analysis. Results: Fifteen patients were evaluated, including 11 males and four females. The average age at presentation was 51.7 ± 20.4 years and the mean follow-up time was 61.5 months (range, 5–286 months). The average resected tumor size at largest dimension was 7.14 cm (range, 2.4–18.7). Twelve of fifteen (80%) patients underwent wide local excision, and nine of the twelve (75%) underwent local radiation therapy. The 1-, 5-, and 10-year OS was 80% (95% CI, 59.8–100), 72% (95% CI, 48.5–95.5), and 72% (95% CI, 48.5–95.5), respectively. The 1-, 5-, and 10-year DSS was 92.3% (95% CI, 77.8–100), 83.1% (95% CI, 61.5–100), and 83.1% (95% CI, 61.5–100), respectively. At last follow-up, 11 patients were alive and ten (90.9%) were disease free. Conclusions: Extraskeletal myxoid chondrosarcoma is a very rare STS most often seen in males and in the extremities. Our cohort was too small to provide meaningful statistical analysis; however, we observed lower rates of local recurrence in patients treated with radiation.

29 January 2024 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
RVRajko S. Vucicevic
Rajko S. Vucicevic
AZAthan G. Zavras
Athan G. Zavras
MFMichael Fice
Michael Fice
ZKZeeshan A. Khan
Zeeshan A. Khan
CGCharles Gusho
Charles Gusho
MCMatthew W. Colman
Matthew W. Colman

7 March 2024 in Surgical Oncology
Verified
Journal Article
Closed access
AYAustin Yu
Austin Yu
LLLinus Lee
Linus Lee
TYThomas Yi
Thomas Yi
MFMichael Fice
Michael Fice
RARohan K. Achar
Rohan K. Achar
ABAlan T. Blank
Alan T. Blank

1 September 2023 in MUSCULOSKELETAL SURGERY
Verified
Journal Article
Closed access
PDF file
LLL. Lee
L. Lee
TYT. Yi
T. Yi
MFMichael Fice
Michael Fice
RAR. K. Achar
R. K. Achar
CJC. Jones
C. Jones
ABA. T. Blank
A. T. Blank

4 August 2023 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
VFVincent P. Federico
Vincent P. Federico
NTNoe Trevino
Noe Trevino
AZAthan G. Zavras
Athan G. Zavras
MFMichael Fice
Michael Fice
ABAlexander J. Butler
Alexander J. Butler
MCMatthew W. Colman
Matthew W. Colman

1 April 2021 in JBJS Case Connector
Verified
Journal Article
Closed access
MFMichael Fice
Michael Fice
VPVishal Patel
Vishal Patel
JSJoanna Solarewicz
Joanna Solarewicz
CGCharles Gusho
Charles Gusho
IMIra Miller
Ira Miller
ABAlan Blank
Alan Blank
Case: A 58-year-old man with rheumatoid arthritis (RA) on disease modifying antirheumatic drug therapy presented with chronic right shoulder pain. Magnetic resonance imaging was concerning for rice body disease which was confirmed through histology after intraoperative deltoid bursa resection. Conclusions: Rice bodies can develop regardless of RA symptom severity or the degree of RA medical therapy administered. Therefore, physicians should not disregard rice bodies as a possible cause of symptoms in individuals on appropriate RA medical therapy or who are demonstrating adequate RA symptom and flair control.